A bold new initiative is taking shape in Europe, aiming to revolutionize the way we tackle Alzheimer's disease (AD). With a rising prevalence of AD, expected to surpass 19 million cases in Europe by 2050, the need for timely and effective management is more urgent than ever.
Enter the ACCESS-AD consortium, a collaborative effort led by King's College London, Amsterdam UMC, Siemens Healthineers, and Gates Ventures, with funding from the European Commission's Innovative Health Initiative. This ambitious project has a budget of over €37 million over five years, with King's College London receiving €2.8m.
But here's where it gets controversial: the current healthcare system is already struggling to keep up with the demand for timely diagnostic testing, brain imaging, and structured clinical follow-up. This delay in treatment can lead to poorer outcomes for patients. ACCESS-AD aims to change that, by accelerating innovation and ensuring equitable access to care.
The project will integrate brain imaging, blood-based biomarkers, digital monitoring tools, AI-driven decision support, and real-world evidence to create a seamless patient journey. By combining these advanced technologies, ACCESS-AD aims to speed up diagnostic confirmation and support the safe administration of disease-modifying therapies (DMTs).
"We believe that by considering technological innovation alongside economic, ethical, and regulatory perspectives, we can create a sustainable and equitable pathway for implementing new AD diagnostics and therapies," says Professor Dag Aarsland, Professor of Old Age Psychiatry and Head of the Centre for Healthy Brain Ageing at King's College London.
A key aspect of the project is the utilization of advanced neuroimaging techniques, coupled with expanded use of fluid and digital biomarkers. This approach will enable early and accurate patient identification, leading to timely diagnosis and personalized treatment plans. ACCESS-AD also aims to make advanced tools, traditionally available only in specialist centers, more accessible to primary care and underserved regions.
Dr. Richard Siow, Director of Ageing Research at King's (ARK), emphasizes the importance of this initiative: "By bringing together experts from academia, clinical practice, and industry across Europe, ACCESS-AD will identify novel personalized interventions to prevent cognitive decline and promote healthy brain aging."
ACCESS-AD's pan-European AD registry, built on the InRAD platform, will collect real-world data from over 500 patients across various health systems. This data will provide insights into safety, clinical evolution, and treatment outcomes under routine clinical conditions. The registry will also support a pilot study testing the combination of DMTs with a multicomponent lifestyle intervention and nutritional supplement strategy.
Recognizing the need for equitable and scalable implementation, ACCESS-AD incorporates health-economic modeling, regulatory development, ethical considerations, and sustainability assessments. European Patient Advisory Boards will ensure that patient and carer needs and values are central to the project.
"ACCESS-AD is a game-changer, bringing cutting-edge diagnostics and personalized treatment to a scale that can make a real impact. By integrating neuroimaging with fluid and digital biomarkers, we can identify those at risk earlier and guide them towards tailored treatment pathways that combine disease-modifying therapies with lifestyle and nutritional strategies," says Dr. Zunera Khan, Research Portfolio Lead in the Centre for Healthy Brain Ageing at King's.
Professor Mariam Molokhia, a clinical epidemiologist and GP in the School of Life Course and Population Sciences at King's, is a Consortium Co-investigator leading the primary care and epidemiology aspects of the clinical studies.
This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101253010, with funding from the European Union's Horizon Europe research and innovation program, and COCIR, EFPIA, Europa Bío, MedTech Europe, and Vaccines Europe.
So, what do you think? Is this initiative a step towards a brighter future for Alzheimer's patients and their families? We'd love to hear your thoughts in the comments below!
